Physician profile
Stephen Long
NPI 1285613257
$3,484.97
in general payments reported to CMS, 2019-2025
14 companies · $588 in 2025
The $588 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $97.95 · 2021: $620 · 2022: $297 · 2023: $600 · 2024: $903 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607 · Travel and Lodging: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.75 |
| Travel and Lodging | $483.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,253.18 | 2019-2025 | Wavewriter Alpha Prime 16, Coveredge 32, General - Pain Management |
| Pacira Pharmaceuticals Incorporated | $661.86 | 2024 | Exparel, Iovera |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.20 | 2023-2025 | Relistor |
| Averitas Pharma INC. | $100.33 | 2024-2025 | Qutenza |
| Assertio Therapeutics, INC. | $81.46 | 2019-2020 | |
| Forte Bio-Pharma LLC | $71.03 | 2019-2020 | |
| Si-Bone, INC. | $70.74 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $33.56 | 2021 | |
| Spr Therapeutics, INC | $21.92 | 2025 | Sprint Pns System |
| Kaleo, INC. | $17.80 | 2019 | |
| Grt US Holding, INC. | $17.54 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.10 | 2025 | |
| Pfizer INC. | $13.79 | 2019 | |
| Horizon Therapeutics Plc | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.